{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T20:46:25Z","timestamp":1782506785809,"version":"3.54.5"},"reference-count":14,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2019,2,21]],"date-time":"2019-02-21T00:00:00Z","timestamp":1550707200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Intl Journal of Cancer"],"published-print":{"date-parts":[[2019,8,15]]},"abstract":"<jats:p>Talimogene laherparepvec (T\u2010VEC) is a modified herpes simplex virus, type 1 (HSV\u20101), which can be administered intralesionally in patients with stage IIIB\/C\u2010IVM1a unresectable melanoma (EMA label). The phase 3 OPTiM registration study showed an overall response rate (ORR) of 26%. Since December 2016, 48 eligible patients started treatment at the Netherlands Cancer Institute. We included 26 patients in this study with a follow up time\u2009\u22656 months, reporting Overall Response Rate (ORR), Disease Control Rate (DCR), Adverse Events (AE), prior treatment for melanoma and baseline characteristics, documented in a prospectively maintained database. In house developed treatment protocol consists of clinical evaluation, periodic PET\u2010CT and histological biopsies for response evaluation. Median follow\u2010up was 12.5 months. Of 26 patients, 16 (61.5%) had a Complete Response (CR) as their best response. Seven (26.9%) patients had a Partial Response (PR) as their best response, 1 (3.8%) patient Stable Disease (SD) and 2 (7.7%) patients Progressive Disease (PD). Best ORR was 88.5%. DCR was 92.3%. Grade 1\u20132 AEs occurred in all patients. Mostly, these consisted of fatigue, influenza\u2010like symptoms and injection site erythema. All patients underwent prior treatment. Prior treatment did not influence response or toxicity of T\u2010VEC. Best ORR for T\u2010VEC monotherapy at our institute was 88.5% with 61.5% achieving a CR. This prospective study for T\u2010VEC in early metastatic (stage IIIB\/C\u2010IVM1a) melanoma demonstrated superior results to the phase 3 OPTiM study and confirms the role of oncolytic immunotherapy for melanoma.<\/jats:p>","DOI":"10.1002\/ijc.32172","type":"journal-article","created":{"date-parts":[[2019,1,29]],"date-time":"2019-01-29T22:28:22Z","timestamp":1548800902000},"page":"974-978","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":85,"title":["High response rates for T\u2010VEC in early metastatic melanoma (stage IIIB\/C\u2010IVM1a)"],"prefix":"10.1002","volume":"145","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0703-5092","authenticated-orcid":false,"given":"Viola","family":"Franke","sequence":"first","affiliation":[{"name":"Department of Surgical Oncology The Netherlands Cancer Institute\u2010Antoni van Leeuwenhoek  Amsterdam The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danique M.S.","family":"Berger","sequence":"additional","affiliation":[{"name":"Department of Head and Neck Surgery and Oncology The Netherlands Cancer Institute\u2010Antoni van Leeuwenhoek  Amsterdam The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W. Martin C.","family":"Klop","sequence":"additional","affiliation":[{"name":"Department of Head and Neck Surgery and Oncology The Netherlands Cancer Institute\u2010Antoni van Leeuwenhoek  Amsterdam The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernies","family":"van der Hiel","sequence":"additional","affiliation":[{"name":"Departments of Nuclear Medicine The Netherlands Cancer Institute\u2010Antoni van Leeuwenhoek  Amsterdam The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bart A.","family":"van de Wiel","sequence":"additional","affiliation":[{"name":"Department of Pathology The Netherlands Cancer Institute\u2010Antoni van Leeuwenhoek  Amsterdam The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylvia","family":"ter Meulen","sequence":"additional","affiliation":[{"name":"Department of Surgical Oncology The Netherlands Cancer Institute\u2010Antoni van Leeuwenhoek  Amsterdam The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel W.J.M.","family":"Wouters","sequence":"additional","affiliation":[{"name":"Department of Surgical Oncology The Netherlands Cancer Institute\u2010Antoni van Leeuwenhoek  Amsterdam The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Winan J.","family":"van Houdt","sequence":"additional","affiliation":[{"name":"Department of Surgical Oncology The Netherlands Cancer Institute\u2010Antoni van Leeuwenhoek  Amsterdam The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander C.J.","family":"van Akkooi","sequence":"additional","affiliation":[{"name":"Department of Surgical Oncology The Netherlands Cancer Institute\u2010Antoni van Leeuwenhoek  Amsterdam The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2019,2,21]]},"reference":[{"key":"e_1_2_5_2_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.58.3377"},{"key":"e_1_2_5_3_1","first-page":"11","article-title":"Critical analysis of an oncolytic herpesvirus encoding granulocyte\u2010macrophage colony stimulating factor for the treatment of malignant melanoma","volume":"3","author":"Hughes T","year":"2014","journal-title":"Oncolytic Virother"},{"key":"e_1_2_5_4_1","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-016-0158-5"},{"key":"e_1_2_5_5_1","doi-asserted-by":"publisher","DOI":"10.2217\/fon.10.66"},{"key":"e_1_2_5_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2017.11.007"},{"key":"e_1_2_5_7_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1103782"},{"key":"e_1_2_5_8_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1203421"},{"key":"e_1_2_5_9_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1003466"},{"key":"e_1_2_5_10_1","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-016-0116-2"},{"key":"e_1_2_5_11_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.24.3675"},{"key":"e_1_2_5_12_1","doi-asserted-by":"publisher","DOI":"10.2147\/OTT.S115245"},{"key":"e_1_2_5_13_1","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1097\/CMR.0000000000000444","article-title":"Potential clinical and immunotherapeutic utility of talimogene laherparepvec for patients with melanoma after disease progression on immune checkpoint inhibitors and BRAF inhibitors","volume":"28","author":"Chesney J","year":"2018","journal-title":"Melanoma Res"},{"key":"e_1_2_5_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2017.08.027"},{"key":"e_1_2_5_15_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.73.7379"}],"container-title":["International Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fijc.32172","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ijc.32172","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/ijc.32172","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ijc.32172","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,10]],"date-time":"2023-09-10T14:53:36Z","timestamp":1694357616000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/ijc.32172"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2,21]]},"references-count":14,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2019,8,15]]}},"alternative-id":["10.1002\/ijc.32172"],"URL":"https:\/\/doi.org\/10.1002\/ijc.32172","archive":["Portico"],"relation":{},"ISSN":["0020-7136","1097-0215"],"issn-type":[{"value":"0020-7136","type":"print"},{"value":"1097-0215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,2,21]]},"assertion":[{"value":"2018-09-24","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-01-15","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-02-21","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}